Glucotrack announces positive data from feasibility study for implantable continuous glucose monitor

Rutherford, nj, july 25, 2023 (globe newswire) -- - glucotrack, inc. (nasdaq: gctk) (“glucotrack” or the “company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with type 1 and type 2 insulin-dependent diabetes.
GCTK Ratings Summary
GCTK Quant Ranking